Shares of Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $7.00.
Several equities research analysts have recently issued reports on INTS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Monday, October 19th. HC Wainwright raised their price objective on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th.
Get Our Latest Stock Report on INTS
Intensity Therapeutics Stock Performance
Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.10). As a group, equities research analysts predict that Intensity Therapeutics will post -4.32 EPS for the current fiscal year.
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response. The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors.
Featured Stories
- Five stocks we like better than Intensity Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
